drugset
drugset / Trial / NCT01758198

Abatacept Post-marketing Clinical Study in Japan

NCT01758198 ↗

Phase 4 Completed 405 enrolled Bristol-Myers Squibb Ono Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the clinical efficacy including joint damage progression and safety of Abatacept plus Methotrexate (MTX) to placebo plus MTX.

Timeline

Start
2013-04-11
Primary completion
2016-12-26
Completion
2016-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 10 mg/kg Intravenous
Background Methotrexate Small molecule 6 mg —

Indications

rheumatoid arthritis